GlassScriptPhysician profile
James Corbin Ferguson
NPI 1598384703
$1,940.01
in general payments reported to CMS, 2019-2025
14 companies · $829 in 2025
The $829 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,111 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Travel and Lodging: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.20 |
| Travel and Lodging | $671.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $671.81 | 2024 | Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $277.44 | 2024-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $231.87 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $142.59 | 2024-2025 | |
| Novo Nordisk INC | $126.42 | 2024-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $111.93 | 2024-2025 | Rexulti |
| Abbvie INC. | $94.12 | 2025 | |
| Inspire Medical Systems, INC. | $77.07 | 2024 | Inspire |
| Medtronic, INC. | $73.03 | 2024 | Venaseal |
| Glaxosmithkline, LLC. | $43.36 | 2024-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $41.89 | 2025 | |
| Esperion Therapeutics, INC. | $17.50 | 2024 | Nexletol |
| Amgen INC. | $16.76 | 2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $14.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.